Share this video  

IGCS 2022 | Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer

Mansoor R. Mirza, MD, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, discusses key updates in gynecological cancers presented at the European Society for Medical Oncology (ESMO) annual meeting held in Paris, France, including long-term benefit from first-line (1L) maintenance PARP inhibitors from the PAOLOA-1 (NCT02477644), PRIMA (NCT02655016), and SOLO-1 (NCT01844986) trials. This interview took place at the Annual Global Meeting of the International Gynecologic Cancer Society (IGCS 2022) in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.